Alaunos Therapeutics (NASDAQ: TCRT)
Alaunos Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Alaunos Therapeutics Company Info
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.
News & Analysis
Why Alaunos Therapeutics Triumphed On Tuesday
Four of the biotech's top managers reveal they've exercised stock options, and investors are following suit by snapping up shares.
Why Alaunos Therapeutics Stock Is Soaring Today
The biotech is rebounding after yesterday's big sell-off.
Why Alaunos Therapeutics Stock Sank Today
Investors appeared to take profits off the table after the biotech's positive news last week.
Why Alaunos Therapeutics Topped the Market on Tuesday
A specialty cancer therapy developed by the company shows some rather promising results.
Why Alaunos Therapeutics Stock Is Up Yet Again Today
Shorts appear to be moving to the sidelines ahead of an upcoming presentation.
Why Alaunos Therapeutics Stock Is Tumbling Today
The biotech's stock is giving back some of its recent gains.
Why Alaunos Therapeutics' Shares Jumped 48.9% This Week
The rise was part of an upswing that began earlier this year.
Why Ziopharm Oncology Shares Rose 10.5% on Wednesday
The clinical-stage biotech saw a slight bounce-back from its lows of last week.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.